Zosano Pharma Corporation announced that an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine” was published in The Journal of Headache and Pain. This open-label, multicenter observational study was designed to evaluate the safety and efficacy of the repeated use of Qtrypta™ in adults with migraine who had historically experienced at least 2 migraine attacks per month. The tolerability and efficacy results in this long-term study were consistent with the results observed in the Phase 2/3 ZOTRIP study. A total of 335 participants treated at least one migraine attack, and in total 5,963 migraine attacks were treated over the course of the study. The primary outcome measure was the percentage of participants experiencing treatment emergent adverse events over 12?months. Secondary outcomes included the percentage of migraine attacks for which pain freedom and most bothersome symptom freedom were achieved at two?hours post-dose, and the percentage for which pain relief was achieved at two?hours post-dose. Participants achieved pain relief at two hours post-dose in 81% of migraine attacks, pain freedom in 44% of attacks, and most bothersome symptom freedom in 62% of attacks. The majority of participants experienced cutaneous application site reactions where the Qtrypta patch was applied, of which more than 95% were rated as mild. More than 80% of swelling and redness incidents were resolved (rated as zero) by 48?hours following application.